Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma
Abstract
Background: Regorafenib is a second-line therapy drug used for advanced hepatocellular carcinoma (HCC). Unfortunately, the survival benefit of the patients receiving this treatment is modest, which may be attributed to drug resistance. In the present study, Sphingosine kinase 2 (SphK2) was targeted to reverse regorafenib-resistance in HCC. Methods: The function of SphK2 and sphingosine-1-phosphate (S1P), the catalytic product of SphK2 in...
Paper Details
Title
Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma
Published Date
Jun 24, 2020
Journal
Volume
10
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History